In vitro cytotoxicity assessment of ruxolitinib on oligodendrocyte precursor cell and neural stem/progenitor cell populations

JAK-STAT signaling cascade has emerged as an ideal target for the treatment of myeloproliferative diseases, autoimmune diseases, and neurological disorders. Ruxolitinib (Rux), is an orally bioavailable, potent and selective Janus-associated kinase (JAK) inhibitor, proven to be effective to target ac...

Full description

Bibliographic Details
Main Authors: Lim, Cheng-Wei, Hamanaka, Gen, Liang, Anna C., Chan, Su Jing, Ling, King Hwa, Lo, Eng H., Arai, Ken, Cheah, Pike See
Format: Article
Language:English
Published: Elsevier B.V. 2024
Online Access:http://psasir.upm.edu.my/id/eprint/114275/
http://psasir.upm.edu.my/id/eprint/114275/1/114275.pdf
_version_ 1848866445507690496
author Lim, Cheng-Wei
Hamanaka, Gen
Liang, Anna C.
Chan, Su Jing
Ling, King Hwa
Lo, Eng H.
Arai, Ken
Cheah, Pike See
author_facet Lim, Cheng-Wei
Hamanaka, Gen
Liang, Anna C.
Chan, Su Jing
Ling, King Hwa
Lo, Eng H.
Arai, Ken
Cheah, Pike See
author_sort Lim, Cheng-Wei
building UPM Institutional Repository
collection Online Access
description JAK-STAT signaling cascade has emerged as an ideal target for the treatment of myeloproliferative diseases, autoimmune diseases, and neurological disorders. Ruxolitinib (Rux), is an orally bioavailable, potent and selective Janus-associated kinase (JAK) inhibitor, proven to be effective to target activated JAK-STAT pathway in the diseases previously described. Unfortunately, limited studies have investigated the potential cytotoxic profile of Rux on other cell populations within the heterogenous CNS microenvironment. Two stem and progenitor cell populations, namely the oligodendrocyte precursor cells (OPCs) and neural stem/progenitor cells (NSPCs), are important for long-term maintenance and post-injury recovery response of the CNS. In light of the limited evidence, this study sought to investigate further the effect of Rux on proliferating and differentiating OPCs and NSPCs populations. In the present study, cultured rat OPCs and NSPCs were treated with various concentrations of Rux, ranging from 2 μM to 20 μM. The effect of Rux on proliferating OPCs (PDGF-R-α+) and proliferating NSPCs (nestin+) was assessed via a 3-day Rux treatment, whereas its effect on differentiating OPCs (MBP+/PDGF-R-α+) and differentiating NSPCs (neurofilament+) was assessed after a 7-day treatment. Cytotoxicity of Rux was also assessed on OPC populations by examining its influence on cell death and DNA synthesis via YO-PRO-1/PI dual-staining and BrdU assay, respectively. The results suggest that Rux at a dosage above 10 μM reduces the number proliferating OPCs, likely via the induction of apoptosis. On the other hand, Rux treatment from 2.5 μM to 20 μM significantly reduces the number of differentiating OPCs by inducing necrosis. Meanwhile, Rux treatment has no observable untoward impact on NSPC cultures within the dosage range tested. Taken together, OPCs appears to be more vulnerable to the dosage effect of Rux, whereas NSPCs are not significantly impacted by Rux, suggesting a differential mechanism of actions of Rux on the cell types.
first_indexed 2025-11-15T14:20:43Z
format Article
id upm-114275
institution Universiti Putra Malaysia
institution_category Local University
language English
last_indexed 2025-11-15T14:20:43Z
publishDate 2024
publisher Elsevier B.V.
recordtype eprints
repository_type Digital Repository
spelling upm-1142752025-03-10T01:19:03Z http://psasir.upm.edu.my/id/eprint/114275/ In vitro cytotoxicity assessment of ruxolitinib on oligodendrocyte precursor cell and neural stem/progenitor cell populations Lim, Cheng-Wei Hamanaka, Gen Liang, Anna C. Chan, Su Jing Ling, King Hwa Lo, Eng H. Arai, Ken Cheah, Pike See JAK-STAT signaling cascade has emerged as an ideal target for the treatment of myeloproliferative diseases, autoimmune diseases, and neurological disorders. Ruxolitinib (Rux), is an orally bioavailable, potent and selective Janus-associated kinase (JAK) inhibitor, proven to be effective to target activated JAK-STAT pathway in the diseases previously described. Unfortunately, limited studies have investigated the potential cytotoxic profile of Rux on other cell populations within the heterogenous CNS microenvironment. Two stem and progenitor cell populations, namely the oligodendrocyte precursor cells (OPCs) and neural stem/progenitor cells (NSPCs), are important for long-term maintenance and post-injury recovery response of the CNS. In light of the limited evidence, this study sought to investigate further the effect of Rux on proliferating and differentiating OPCs and NSPCs populations. In the present study, cultured rat OPCs and NSPCs were treated with various concentrations of Rux, ranging from 2 μM to 20 μM. The effect of Rux on proliferating OPCs (PDGF-R-α+) and proliferating NSPCs (nestin+) was assessed via a 3-day Rux treatment, whereas its effect on differentiating OPCs (MBP+/PDGF-R-α+) and differentiating NSPCs (neurofilament+) was assessed after a 7-day treatment. Cytotoxicity of Rux was also assessed on OPC populations by examining its influence on cell death and DNA synthesis via YO-PRO-1/PI dual-staining and BrdU assay, respectively. The results suggest that Rux at a dosage above 10 μM reduces the number proliferating OPCs, likely via the induction of apoptosis. On the other hand, Rux treatment from 2.5 μM to 20 μM significantly reduces the number of differentiating OPCs by inducing necrosis. Meanwhile, Rux treatment has no observable untoward impact on NSPC cultures within the dosage range tested. Taken together, OPCs appears to be more vulnerable to the dosage effect of Rux, whereas NSPCs are not significantly impacted by Rux, suggesting a differential mechanism of actions of Rux on the cell types. Elsevier B.V. 2024 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/114275/1/114275.pdf Lim, Cheng-Wei and Hamanaka, Gen and Liang, Anna C. and Chan, Su Jing and Ling, King Hwa and Lo, Eng H. and Arai, Ken and Cheah, Pike See (2024) In vitro cytotoxicity assessment of ruxolitinib on oligodendrocyte precursor cell and neural stem/progenitor cell populations. NeuroToxicology, 105. pp. 10-20. ISSN 0161-813X; eISSN: 1872-9711 https://linkinghub.elsevier.com/retrieve/pii/S0161813X24001001 10.1016/j.neuro.2024.08.004
spellingShingle Lim, Cheng-Wei
Hamanaka, Gen
Liang, Anna C.
Chan, Su Jing
Ling, King Hwa
Lo, Eng H.
Arai, Ken
Cheah, Pike See
In vitro cytotoxicity assessment of ruxolitinib on oligodendrocyte precursor cell and neural stem/progenitor cell populations
title In vitro cytotoxicity assessment of ruxolitinib on oligodendrocyte precursor cell and neural stem/progenitor cell populations
title_full In vitro cytotoxicity assessment of ruxolitinib on oligodendrocyte precursor cell and neural stem/progenitor cell populations
title_fullStr In vitro cytotoxicity assessment of ruxolitinib on oligodendrocyte precursor cell and neural stem/progenitor cell populations
title_full_unstemmed In vitro cytotoxicity assessment of ruxolitinib on oligodendrocyte precursor cell and neural stem/progenitor cell populations
title_short In vitro cytotoxicity assessment of ruxolitinib on oligodendrocyte precursor cell and neural stem/progenitor cell populations
title_sort in vitro cytotoxicity assessment of ruxolitinib on oligodendrocyte precursor cell and neural stem/progenitor cell populations
url http://psasir.upm.edu.my/id/eprint/114275/
http://psasir.upm.edu.my/id/eprint/114275/
http://psasir.upm.edu.my/id/eprint/114275/
http://psasir.upm.edu.my/id/eprint/114275/1/114275.pdf